Dramatic advances in the fields of biochemistry, cell and molecular biology, genetics, biomedical engineering and materials science have given rise to the remarkable new cross-disciplinary field of tissue engineering. Tissue engineering uses synthetic or naturally derived, engineered biomaterials to replace damaged or defective tissues, such as bone, skin, and even organs.
RepRegen™, the ‘smart biomaterials’ company previously known as BioCeramic Therapeutics, announced today that data from an in vitro study has demonstrated that its patented Strontium-based bioactive glass platform promotes osteoblast cell activity and proliferation. If in vivo studies, which are currently underway, demonstrate similar results, then RepRegen believes its platform has the potential to significantly improve the repair and regeneration of hard-tissue, such as bone.
Entelos, Inc., a simulation and modeling company focused on human health, and RegeneMed, Inc., a tissue-based drug discovery and regenerative medicine company, announced today the release of iToxFX™.
Soluble Systems, LLC and the Skin and Wound Allograft Institute, a wholly owned subsidiary of LifeNet Health, have signed a noteworthy agreement to launch TheraSkin™, a biologically active human skin allograft designed to jumpstart healing in chronic and acute wounds.
University of Calgary chemistry professor David Cramb is a step closer to helping solve a complex problem in nanotechnology: the impact nanoparticles have on human health and the environment.
Injuries to joints and cartilage can have serious consequences, including osteoarthritis. Cartilage degeneration in joints is a widespread disease in Germany and worldwide. Prof. Dr. Prasad Shastri is an expert in tissue engineering (TE), tissue construction and tissue cultivation using the body's own cells. He is Professor of Biofunctional Macromolecular Chemistry at the Centre for Biological Signalling Studies (BIOSS), a Cluster of Excellence at the University of Freiburg, where he has been researching for the last year.
Clinical testing and development of novel therapies based on advances in tissue engineering and regenerative medicine that will one day enable the repair and replacement of diseased or damaged human muscle, bone, tendons, and ligaments depends on the availability of good animal models.
For the first time, scientists have performed a detailed long-term evaluation and comparison of two different types of pluripotent stem cells: human embryonic stem cells (hESC) and induced pluripotency stem cells (iPSC). Both cell types are believed to share equal characteristics, abilities and potential to differentiate into nearly 220 different cell types. However, hESC are isolated from early human embryos and iPSC are derived from reprogrammed adult somatic cells which makes them less controversial.
Health care companies that design and manufacture medical devices, equipment, and instruments can now help their technologists, engineers, and other employees conduct research more efficiently and effectively, resulting in greater cost savings and faster development times for new products.
Pluristem Therapeutics Inc. today announced that the results of a pre-clinical study in an animal model of ischemic stroke demonstrated that its PLacental eXpanded (PLX) cell therapy may be an effective treatment for this disorder.
Advances in tissue engineering are offering the promise of being able to restore lost bone and gum tissue following periodontal disease.
For each action, there is an equal and opposite reaction. So after the surge in U.S. troops heading to Afghanistan, there will be an influx of injured veterans returning back home. But the U.S. Department of Defense has recruited its own "soldiers" in the battle against war casualties: a consortium of researchers who are improving care to wounded soldiers as well as the general public.
An award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) will aid a partnership between the University of Cincinnati (UC) and Cincinnati Children's Hospital Medical Center (CCHMC) in finding new ways to use adult stem cells to speed repair of musculoskeletal soft tissue injuries.
Tissue Genesis, Inc., an emerging leader in advanced tissue engineering and cell therapy solutions, and American Medical Systems Holdings, Inc. announced today they have signed an agreement for the research and development of adipose (fat)–derived regenerative cells for use in treating pelvic health disorders.
LifeNet Health, a leading allograft bio-implant company, will nationally launch the CardioGRAFT® decell pulmonary patch with MATRACELL™ technology at the Society of Thoracic Surgeons annual meeting in Ft. Lauderdale, Fla., on January 24.
BioLife Solutions, Inc., a leading developer, manufacturer, and marketer of biopreservation tools for cells, tissues, and organs, and OriGen Biomedical, a leading provider of biologic packaging products for research and clinical blood and cell-based therapies, today announced that the companies will introduce sterile standard and custom biologic packaging products pre-filled with BioLife's serum-free, protein-free HypoThermosol® cell and tissue storage/transport media and CryoStor™ cryopreservation media.
Stanford University School of Medicine scientists have discovered a novel class of compounds that, in experiments in vitro, inhibit replication of the virus responsible for hepatitis C. If these compounds prove effective in infected humans as well, they may dramatically accelerate efforts to confront this virus’s propensity to rapidly acquire drug resistance, while possibly skirting some of the troubling side effects common among therapies in current use and in late-stage development.
Chinese researchers have become the world's fifth most prolific contributors to peer-reviewed scientific literature on clock-reversing regenerative medicine even as a skeptical international research community condemns the practice of Chinese clinics administering unproven stem cell therapies to domestic and foreign patients.
The conflicts in Iraq and Afghanistan have left a terrible legacy: more than 1,200 returning American soldiers have lost one or more limbs. To address this growing national need, researchers at Worcester Polytechnic Institute (WPI) are laying the groundwork for a new generation of advanced prosthetic limbs that will be fully integrated with the body and nervous system.
Researchers from the University of Hong Kong and the Massachusetts Institute of Technology have published a study in the current issue of Cell Transplantation (18:9), now freely available on line at http://www.ingentaconnect.com/content/cog/ct, that explores ways to successfully keep stem cells "forever young" during implantation by slowing their growth, differentiation and proliferation.
BioLife Solutions, Inc., a leading developer, manufacturer, and marketer of biopreservation tools for cells, tissues, and organs, today announced that it has successfully completed audits of its quality systems and GMP production facility in Bothell, Washington by BSI Group and has been issued a certification to ISO 13485:2003, an international standard for quality systems supporting the design, development, and manufacture of medical devices.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.